Israel-based Teva Pharmaceuticals, Iceland’s Actavis, US-based Mylan Laboratories and Indian companies Cipla and Ranbaxy have all made bids, according to reports carried by the Reuters news agency. However,
Ortho-McNeil entered into a collaboration and license agreement with Cellzome in May 2005 and the collaboration was extended for a further year in January 2007. The milestone payment
The program contains a number of development candidates targeting TLRs to activate innate immunity. VentiRx expects to develop its first two candidates in oncology and allergy. Array will
The study, being conducted at UCSF Medical Center, is enrolling HIV-1 infected subjects with compromised CD4+ cell counts, to determine whether the procedure will create sufficient HIV-1 resistant
Oxford BioMedica said that Oxxon's technology has broad product applications in cancer and infectious diseases and will create new licensing opportunities. Oxxon's lead cancer vaccine, Hi-8 MEL, has
Tyrima is a member of a novel class of drugs known as reversible inhibitors of monoamine oxidase A, or RIMAs. The single-dose, placebo-controlled trial evaluated Tyrima in 41
A vaccine for ricin is considered by many the best way to prospectively protect certain human populations who are at risk of exposure. Since this vaccine would presumably
The studies were conducted by the Fraunhofer USA Center for Molecular Biotechnology (CMB), the contract research organization led by Vidadi Yusibov, through which BioTech executes its vaccine-related development
Phase I clinical trials with anatibant in healthy volunteers and patients with TBI demonstrated a favorable clinical safety, tolerability and pharmokinetic profile, according to the company. Xytis plans
The subpoenas relate to investigations into the sales and marketing of Risperdal by Janssen, Topamax by Ortho-McNeil and Natrecor by Scios – each subsidiaries of Johnson & Johnson.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.